Effects of Early Thyroxine Treatment on Development and Growth at Age 10.7 Years: Follow-Up of a Randomized Placebo-Controlled Trial in Children With Down's Syndrome
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CONTEXT: In 2-year-old children with Down's syndrome (DS), early T4 treatment was found to result in slightly better motor development and growth. OBJECTIVES: This study sought to determine long-term effects of early T4 treatment on development and growth in children with DS with either an elevated or normal neonatal TSH concentration. DESIGN: Patients received a single follow-up visit 8.7 years after a randomized placebo-controlled trial (RCT) comparing T4 and placebo treatment during the first 2 years of life. SETTING: Dutch Academic Hospital. PARTICIPANTS: All children who completed the RCT (N = 181, of 196 randomly assigned children) were invited for the follow-up study. A total of 123 participants enrolled, at a mean age of 10.7 years. INTERVENTIONS: T4 or placebo treatment from the neonatal period until 2 years. MAIN OUTCOME MEASURES: Primary: mental and motor development. Secondary: communication skills, fine-motor coordination, height, weight, and head circumference (HC). Outcomes were compared between T4- and placebo-treated children, and between treatment groups with either a normal (<5 mIU/L), or elevated (≥ 5 mIU/L) TSH concentration at original trial entry. RESULTS: Mental or motor development, communication skills, or fine-motor coordination did not differ between T4- (N = 64) and placebo-treated children (N = 59). T4-treated children had a larger HC (50.4 vs 49.8 cm, P = .04) and tended to be taller (133.2 vs 131.1 cm, P = .06). These differences were somewhat greater in children with TSH ≥ 5 mIU/L (HC: T4, 50.5 vs placebo, 49.7 cm; P = .01; height: T4, 133.8 vs placebo, 130.8 cm; P = .02), but were not found in children with TSH <5 mIU/L (HC: T4, 50.1 vs placebo, 50.0 cm; P = .75; height: T4, 132.1 vs placebo, 131.6 cm; P = .22). CONCLUSIONS: Early T4 treatment of children with DS does not seem to benefit mental or motor development later in life. However, the positive effect on growth is still measurable, especially in children with an elevated plasma TSH concentration in the neonatal period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Zoeller, R. T., & Rovet, J. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2004.01243.x · Cited by 605
Abnormalities of thyroid function in infants with Down syndrome
Fort, P., Lifshitz, F., Bellisario, R., Davis, J., Lanes, R., Pugliese, M., Richman, R., Post, E. M., & David, R. (1984) · The Journal of Pediatrics · doi:10.1016/s0022-3476(84)80544-2 · Cited by 212
Kempers, M. J. E., van der Sluijs Veer, L., Nijhuis-van der Sanden, M. W. G., Kooistra, L., Wiedijk, B. M., Faber, I., Last, B. F., de Vijlder, J. J. M., Grootenhuis, M. A., & Vulsma, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1209 · Cited by 122 · cited 1×
“Overt hypothyroidism is a clear indication for treatment with T4 to ensure optimal brain development (infants), growth (children), and metabolism (all ages) [5].”
BackgroundSelf-citationLower Neonatal Screening Thyroxine Concentrations in Down Syndrome Newborns
van Trotsenburg, A. S. P., Vulsma, T., van Santen, H. M., Cheung, W., & de Vijlder, J. J. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021303 · Cited by 118
Cited by
Prado, E. L., Larson, L. M., Cox, K., Bettencourt, K., Kubes, J. N., & Shankar, A. H. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30361-4 · Cited by 173
Early thyroxine treatment in Down syndrome and thyroid function later in life
Zwaveling-Soonawala, N., Witteveen, M. E., Marchal, J. P., Klouwer, F. C. C., Ikelaar, N. A., Smets, A. M. J. B., van Rijn, R. R., Endert, E., Fliers, E., & van Trotsenburg, A. S. P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0858 · Cited by 23
Self-citationState-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Metadata
- Authors
- Marchal, J. P., Maurice-Stam, H., Ikelaar, N. A., Klouwer, F. C. C., Verhorstert, K. W. J., Witteveen, M. E., Houtzager, B. A., Grootenhuis, M. A., & van Trotsenburg, A. S. P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-12
- Volume
- 99
- Issue
- 12
- Pages
- E2722-E2729
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2049835250
- Cited by
- 42
- References
- 5
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.